The Situation of Re-infection of Helicobacter Pylori After Successful Eradication

Phase

N/A

Condition

Helicobacter Pylori

Treatment

N/A

Clinical Study ID

NCT04029493

2018SDU-QILU-G116

Ages 18-70
All Genders

Study Summary

The patients who accept the quadruple eradication program of the helicobacter pylori and success to eradicate helicobacter pylori will be followed-up to observe the situation of re-infection of helicobacter pylori.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients, aged between 18 and 70 years old, with positive H. pylori infection that wasnot eradicated by previous therapies are included. The H. pylori infection isconfirmed by the positive rapid urease test or 13C-breath test.

Exclusion

Exclusion Criteria:

Patients with significant underlying disease including liver, cardiac, pulmonary, andrenal diseases, neoplasia, coagulopathy and genetic diseases, history of gastricsurgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history ofallergic reactions to any of the medications used in this protocol. Patientspreviously treated with H. pylori eradication regimens or those unwilling toparticipate in the study were also excluded.

Study Design

September 01, 2018

September 30, 2021

Study Description

The patients with helicobacter pylori accepted he quadruple eradication program of the helicobacter pylori.They will be followed-up from 1 year to 5 years to observe the situation of re-infection of helicobacter pylori.The rate of the re-infection will be described by frequency and percentage.

Connect with a study center

Qilu Hospital of Shandong University
Jinan, Shandong 257000
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.